Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Verrica Pharmaceuticals Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
VRCA
Nasdaq
2830
www.verrica.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
- Jul 9th, 2025 5:00 am
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
- Jul 1st, 2025 5:00 am
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA): Are Analysts Optimistic?
- Jun 12th, 2025 7:31 am
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
- May 28th, 2025 6:00 am
Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlights: Strong YCANTH Demand and ...
- May 14th, 2025 1:16 am
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
- May 13th, 2025 3:25 pm
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
- May 13th, 2025 2:05 pm
Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates
- May 12th, 2025 3:15 pm
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
- May 7th, 2025 6:00 am
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
- Apr 30th, 2025 6:00 am
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
- Apr 7th, 2025 6:00 am
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
- Apr 2nd, 2025 2:05 pm
Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now
- Apr 1st, 2025 7:55 am
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
- Mar 31st, 2025 6:00 am
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
- Mar 26th, 2025 5:00 am
Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ...
- Mar 12th, 2025 1:08 am
Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates
- Mar 11th, 2025 3:25 pm
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
- Mar 11th, 2025 2:05 pm
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
- Mar 3rd, 2025 5:00 am
Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?
- Feb 27th, 2025 8:00 am
Scroll